An interventional study of open-label placebo and Treatment as usual in Adolescent Idiopathic Scoliosis (AIS), sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to participants aged 10 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-03-13.
Sponsored by University of California, San Francisco · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 153 studies in Scoliosis with a site in United States — 42 open to participants now, 51 under way, 2 of them phase 3. Scoliosis · United States.
Among the 153 studies in Scoliosis with a site in United States, this one is the 38th largest by planned enrollment of the 91 interventional ones that give a count, is one of 7 that started in 2024, is one of 65 with no phase, reaches primary completion later than 14 of the 50 other live ones, and was the 139th registered.
660 studies on the registry are indexed under Scoliosis; 185 are open to participants now.
Browse Scoliosis studies →42 of the 153 studies in Scoliosis with a site in United States are open now. Recruiting first, the newest first:
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 14–26
Thinks Works, PBC · Sites in United States
Ages 9–16
Columbia University · Sites in United States
Ages 10–19
Senthil Sadhasivam · Sites in United States
Ages 10–18
Children's Hospital Los Angeles · Sites in United States
Ages 8–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 117 Scoliosis studies recruiting now, 23 (20%) set no upper age limit and 88 (75%) stop at 75 or younger; 98 take children under 18; 14 take healthy volunteers.
This study: 10 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
153 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 6 · Phase 4 15
First in 1998; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 64 is above the median of 45 across 386 interventional studies indexed under Scoliosis.
Median enrollment 58 across the 91 interventional studies, 100 across the 62 observational. Of the 85 that completed or were terminated, 35 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 153 have an industry lead sponsor. The 10 most frequent:
University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.
Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.
University of California, San Francisco has 2 studies filed under Scoliosis — fewer than ten, so there is no comparison to draw.
20 of the studies in Scoliosis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07217873Phase 3Columbia UniversityIntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study | 2027-08-31 |
| NCT00738439International Spine Study Group FoundationProspective, Multi-Center Adult Spinal Deformity Outcomes Database Registry | 2026-12 |
| NCT06910228Joseph D. TobiasChanges in Cerebral Oxygenation Related to Intraoperative Position Changes | 2026-12 |
| NCT06365892University of California, San FranciscoOpen-label Placebo (COLP) for Pain in Adolescent Idiopathic Scoliosis (AIS) Surgery+Surgical Treatment of Idiopathic Scoliosis | 2026-12 |
| NCT03017755Mayo ClinicScoliosis Survey to Development Treatment Decision Tool | 2026-12-01 |
Add all 20 to your calendar (.ics) → With an account.
Among the 153 studies in Scoliosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to investigate the effects of conditioning with open-label placebos on standard postoperative treatment for patients undergoing surgery for idiopathic scoliosis in a randomized controlled, 6-week trial with 64 AIS patients randomly assigned to one of two arms: Open-label Placebo (COLP) + treatment as usual TAU / TAU control. The study involves collecting data from your child's medical record. At each regular clinic visit, the patient clinical data will be collected by the research coordinator. Surveys will be collected including:• PROMIS for the age group 10 to 18 years.
Interventional (clinical trial): Subject will be randomly assigned using permuted blocks (block size of 4). Before usage, random assignments will be created, stored in sealed envelopes, and numbered (1, 2, etc.). There will be stratified randomization: Later on, stratification will be incorporated into the analysis. 32 people will be in the group taking the placebo pills in addition to standardized treatment and 32 people will be in the group with standardized treatment alone.
Hypothesis: Open-label Placebo (COLP) \< treatment as usual (TAU) control. Secondary Aims Analysis Plan: There are three secondary aims in this study.
Aim 1. To determine whether 6 weeks of Open-label Placebo (COLP) results in significantly reduced opioid consumption compared to treatment as usual. To test this aim, the investigators will conduct a t-test comparing mean opioid use over the 6 weeks of follow up. In secondary analyses, the investigators will adjust for any baseline factors including gender, age, symptom severity or type of surgery that could be a confounding variable.
1a. To determine if 6 weeks of Open-label Placebo (COLP) results in reduced opioid consumption compared to treatment as usual. Hypothesis: Open-label Placebo (COLP) \< treatment as usual (TAU) control.
Secondary Aims Analysis Plan: There are three secondary aims in this study.
Secondary Aim 1: Determine if there are significant differences in time to independence with physical therapy, length of stay, time to return to school, urinary retention, constipation, oxygen requirement, and number of contacts with medical team in Open-label Placebo (COLP) compared to treatment as usual (TAU).
Secondary Aim 2: Determine if there is an association between preoperative pain catastrophization, kinesiophobia, positive/negative affect, anxiety, and/or depression and response to Open-label Placebo (COLP) and/or treatment as usual (TAU).
Secondary Aim 3: Determine if there is an association between postoperative PROMIS scores, anxiety, and/or depression in open-label placebo (COLP) compared to treatment as usual (TAU).
Primary Objectives The primary objectives of this study are to: (1) to determine whether 6 weeks of conditioning with open-label placebo (COLP) results in reduced opioid consumption (amount and duration) compared to treatment as usual (TAU) control and (2) to determine whether 6 weeks of Open-label Placebo (COLP) compared to treatment as usual (TAU) results in different clinical outcomes.
Secondary Objectives
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible for enrollment, patients must meet all of the following inclusion criteria:
Exclusion Criteria:
If any of the following exclusion criteria are met, the patient is not eligible for the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo will be supplied as a 330mg tablet (manufactured by Consolidated Midland Corporation). Each oral opioid dose is a 5mg Oxycodone tablet. Patients will take placebo with each oral opioid intake and 3 additional times per day beginning on POD 1. Investigator shall never prescribe ibuprofen. Investigator shall always prescribe Tylenol 625mg every 8hrs (PRN).
Other: open-label placebo · Other: Treatment as usual
Treatment As Usual (TAU) subjects will receive equal access to opioid and non-opioid analgesics. The preferred oral opioid dose is a 5mg Oxycodone pill. Subjects will take a placebo with each oral opioid dose and additional three times per day beginning on POD 1.
Other: Treatment as usual
Placebo will be supplied as a 330mg tablet (manufactured by Consolidated Midland Corporation). Patients will take placebo with each oral opioid intake and 3 additional times per day beginning on POD 1.
Also known as: Inactive drug, Inactive medicine, Inactive substance, Sugar Pill Test Substance
Each oral opioid dose is a 5mg Oxycodone tablet. Investigator shall never prescribe ibuprofen. Investigator shall always prescribe Tylenol 625mg every 8hrs (PRN).
The total amount of opioids consumed in oral morphine equivalents (OMEs) following surgery
Oral morphine equivalents (OMEs) are values that represent the potency of an opioid dose relative to morphine. Using OMEs provides a standardized method for converting between various opiate medications. Each oral opioid dose is a 5mg Oxycodone tablet prescribed 6 times per day pro re nata. Participants will record the number of oral opioids taken each day for 6 weeks following surgery beginning on Post-op Day 1 (POD1). This data will be collected and converted into OMEs for comparison.
Time frame: from admission to 6 weeks post-operatively
Weekly level of mobility and change from baseline in mobility on the Patient-Reported Outcome Measurement Information System (PROMIS) Numeric Rating Scale Pediatric Mobility Short Form 7a at week 6.
the PROMIS Pediatric Mobility SF 7a is a validated, self-reported instrument that consists of 7 items rating mobility on average over the past 7 days from 4 (With no trouble) to 0 (not able to do). Weekly level of mobility = mobility score reported at each week Change = (Week 6 Score - Baseline Score).
Time frame: weekly from admission to 6 weeks post-operatively
Weekly level of anxiety and change from baseline in anxiety levels on the Patient-Reported Outcome Measurement Information System (PROMIS) Numeric Rating Scale Anxiety Short Form 8a at week 6.
the PROMIS Anxiety SF 8a is a validated, self-reported instrument that consists of 8 items rating anxiety on average over the past 7 days from 1 (never) to 5 (almost always). Weekly level of anxiety = anxiety score reported at each week Change = (Week 6 Score - Baseline Score).
Time frame: weekly from admission to 6 weeks post-operatively
Weekly level of depressive symptoms and change from baseline in depressive symptoms on the Patient-Reported Outcome Measurement Information System (PROMIS) Numeric Rating Scale Depressive Symptoms Short Form 8a at week 6.
the PROMIS Depressive Symptoms SF 8a is a validated, self-reported instrument that consists of 8 items rating depressive symptoms on average over the past 7 days from 1 (never) to 5 (almost always). Weekly level of depressive symptoms = depressive symptoms score reported at each week Change = (Week 6 Score - Baseline Score).
Time frame: weekly from admission to 6 weeks post-operatively
The duration of time in days following surgery until patients establish Independence with Physical Therapy
Participants will be treated by physical therapy services after surgery until their physical therapist determines that they no longer require physical therapy services. Duration of time to independence with physical therapy is equal to the POD # where physical therapist determines formal PT is no longer required.
Time frame: from admission to final physical therapy assessment, up to 6 weeks
The length of time in days following surgery until discharge from the hospital
Participants will be admitted to the hospital following surgery until they are cleared for discharge from a medical standpoint. Length of stay = POD # that patient is discharged
Time frame: from admission to discharge, up to 6 weeks
The length of time in days following surgery until participant returns to school
Participants will record the date on which they return to school after surgery. The POD # on date of return to school = the length of time to return to school. The amount of time it takes to return to school can be used as a proxy for whether participants are struggling with their pain or not.
Time frame: from admission to date of return to school, up to 6 weeks post-operatively
Whether participants experience urinary retention following surgery.
Participants will be assessed in hospital to determine whether or not they experience urinary retention post-surgery, a potential side effect of opioid consumption. The urinary retention determination will be a yes/no answer.
Time frame: during hospitalization until discharge, up to 6 weeks
Whether participants experience constipation measured by the number of days between surgery and first bowel movement
Participants will record the number of days between surgery and first bowel movement to assess whether they experience constipation, a potential side effect of opioid consumption.
Time frame: from admission to date of first bowel movement, up to 6 weeks post-operatively
Whether participants experience an oxygen requirement and the duration of the requirement following surgery.
Participants will be assessed in hospital for whether or not they have an oxygen requirement and the duration of requirement. The oxygen requirement will be a yes/no answer. If yes, the number of days that oxygen is required will be recorded for the duration.
Time frame: during hospitalization until discharge, up to 6 weeks
Plan to share: No
Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 29 months after the start.
Of 224 non-industry interventional studies with no phase under Scoliosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 58. This study's planned 29 months is above that.
Counting every sponsor, half of 234 studies reached it within 22 months; a quarter within 8 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco →